The differences in metabolic side effects and cardiovascular risk resulting from antipsychotics make the initial choice of medication important in controlling long-term effects from treatments used for schizophrenia, researchers said here at the 22nd European College of Neuropsychopharmacology (ECNP) Congress.
W. Wolfgang Fleischhacker, MD, Biological Psychiatry Department, Medical University Innsbruck, Innsbruck, Austria, and colleagues analysed data from the European First Episode Schizophrenia Trial (EUFEST) study to determine the effects of several first- and second-generation antipsychotics on cardiovascular risk factors in patients with or without metabolic syndrome (MS) risk. Results of the study were presented on September 14.
READ MORE @ DOCTOR'S GUIDE
Showing posts with label metabolic side effects. Show all posts
Showing posts with label metabolic side effects. Show all posts
Wednesday, September 16, 2009
Sunday, April 19, 2009
Alzheimer’s Patients on Atypical Antipsychotics Experience “Significant” Weight Gain
Some newer, atypical, or second-generation, antipsychotic medications have been found to have two serious adverse reactions. The drugs both lower so-called “good” cholesterol and cause weight gain in older Alzheimer patients.
HealthDay News reports that in a study of over 400 elderly patients, medications such as Zyprexa (olanzapine) and Seroquel (quetiapine) were both linked to “significant” weight gain, saying that those patients specifically taking Zyprexa “experienced increases in waist circumference and declines in HDL cholesterol,” as well. The study also revealed that the weight gain correlated to the amount of time the patient was on the medication; the longer the patient was taking the drug, the more weight gained, said HealthDay News.
The findings from the Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) study, were funded by the U.S. National Institute of Mental Health (NIMH), said HealthDay News, and appear in the April 15 issue of the American Journal of Psychiatry. “These findings are especially troubling, because antipsychotics are associated with a higher risk of death and cerebrovascular adverse events in patients with dementia. They’re often used to minimize disruptive symptoms (such as psychosis or agitation), but patients should be monitored more closely,” said lead investigator Dr. Lon S. Schneider, in an American Psychiatric Association news release, quoted HealthDay News. The team noted that similar “metabolic side effects” have been seen in schizophrenia patients taking the newer antipsychotics, said HealthDay News.
READ MORE @ NEWS INFERNO
HealthDay News reports that in a study of over 400 elderly patients, medications such as Zyprexa (olanzapine) and Seroquel (quetiapine) were both linked to “significant” weight gain, saying that those patients specifically taking Zyprexa “experienced increases in waist circumference and declines in HDL cholesterol,” as well. The study also revealed that the weight gain correlated to the amount of time the patient was on the medication; the longer the patient was taking the drug, the more weight gained, said HealthDay News.
The findings from the Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) study, were funded by the U.S. National Institute of Mental Health (NIMH), said HealthDay News, and appear in the April 15 issue of the American Journal of Psychiatry. “These findings are especially troubling, because antipsychotics are associated with a higher risk of death and cerebrovascular adverse events in patients with dementia. They’re often used to minimize disruptive symptoms (such as psychosis or agitation), but patients should be monitored more closely,” said lead investigator Dr. Lon S. Schneider, in an American Psychiatric Association news release, quoted HealthDay News. The team noted that similar “metabolic side effects” have been seen in schizophrenia patients taking the newer antipsychotics, said HealthDay News.
READ MORE @ NEWS INFERNO
Monday, November 17, 2008
Medication misuse
As people live longer and suffer from more chronic diseases, the risk of inappropriately using drugs or overmedicating increases among the elderly, says Susan Zieman, geriatric cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine.
Most elderly people are on multiple medications and frequently metabolize drugs differently from younger people, she says. The drugs may build up in their systems and interact with other drugs in unexpected ways.
READ MORE @ BALTIMORE SUN
Most elderly people are on multiple medications and frequently metabolize drugs differently from younger people, she says. The drugs may build up in their systems and interact with other drugs in unexpected ways.
READ MORE @ BALTIMORE SUN
Monday, October 6, 2008
Side-Effects of Antipsychotics
A new federally funded study will examine ways to control the metabolic side effects associated with the use of the newer atypical antipsychotic medications in children with schizophrenia or bipolar disorder.
The use of atypical antipsychotic medications to treat children and adolescents with schizophrenia or bipolar disorder is relatively common, but the side effects associated with them are troubling.
The recent NIMH-funded Treatment of Early Onset Schizophrenia Study (TEOSS) found that two atypical medications were associated with more metabolic side effects than an older generation antipsychotic.
The new grant will test ways in which the metabolic side effects, such as weight gain, insulin sensitivity and other factors that can lead to type 2 diabetes and heart disease, may be controlled or reduced.
READ MORE @ PSYCHCENTRAL
The use of atypical antipsychotic medications to treat children and adolescents with schizophrenia or bipolar disorder is relatively common, but the side effects associated with them are troubling.
The recent NIMH-funded Treatment of Early Onset Schizophrenia Study (TEOSS) found that two atypical medications were associated with more metabolic side effects than an older generation antipsychotic.
The new grant will test ways in which the metabolic side effects, such as weight gain, insulin sensitivity and other factors that can lead to type 2 diabetes and heart disease, may be controlled or reduced.
READ MORE @ PSYCHCENTRAL
Monday, July 28, 2008
Certain Antipsychotics Increase Metabolic, Cardiovascular Risk Factors
Some atypical antipsychotics may be more likely than others to cause metabolic and cardiovascular side effects, according to a study published in the August 2008 issue of Schizophrenia Research.
The study was based on recent data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Jonathan Meyer, MD, University of California at San Diego, San Diego, California, and colleagues compared baseline data with those collected 3 months later from 281 CATIE participants who were randomly assigned to treatment with 1 of 5 antipsychotics -- olanzapine, risperidone, ziprasidone, quetiapine, or perphenazine.
READ MORE @ DOCTOR'S GUIDE
The study was based on recent data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Jonathan Meyer, MD, University of California at San Diego, San Diego, California, and colleagues compared baseline data with those collected 3 months later from 281 CATIE participants who were randomly assigned to treatment with 1 of 5 antipsychotics -- olanzapine, risperidone, ziprasidone, quetiapine, or perphenazine.
READ MORE @ DOCTOR'S GUIDE
Subscribe to:
Posts (Atom)
